News and meta-analysis regarding anti-Beta 2 glycoprotein I antibodies and their determination

International audienceRecent advances allow us to propose antibodies targeting beta-2-glycoprotein I (β2-GPI) as the most specific antibodies associated with anti-phospholipid syndrome (APS). Therefore, there is now a crucial need for powerful biological assays to adequately monitor them. It is well established that these antibodies recognize mainly cryptic epitopes, which requires a great deal of consideration in the choice of laboratory tests to identify these antibodies. To this end, an update on the pathophysiological role of β2-GPI and a meta-analysis were conducted providing an overview of the current progress towards anti-β2-GPI detection

Antiphospholipid antibodies in lupus: an update

International audienc

Antiphospholipid antibodies in lupus: an update

International audienc

The chemiluminescent analyzer IDS-iSYS improves the thrombotic risk assessment of the anti-beta 2 glycoprotein I autoantibodies

International audienc

The chemiluminescent analyzer IDS-iSYS improves the thrombotic risk assessment of the anti-beta 2 glycoprotein I autoantibodies

International audienc

Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases

International audienceAntiphospholipid (aPL) autoantibodies are uncommon in systemic autoimmune diseases (SADs). However, the European PRECISESADS study provides the opportunity to better characterize this rare association. The study was composed of 1818 patients with SADs including 453 with systemic lupus erythematosus (SLE), 359 with rheumatoid arthritis (RA), 385 with systemic sclerosis (SSc), 367 with Sjögren's syndrome (SjS), 94 with mixed connective tissue disease (MCTD), and 160 with undifferentiated connective tissue disease (UCTD). Assays used for aPL determination include the lupus anticoagulant (LAC) analysis using the dilute Russell's viper venom time (dRVVT) assay plus anti-cardiolipin (aCL) and anti-aβ2GPI autoantibodies of IgG and IgM isotype. Information regarding clinical and biological characteristics of SAD patients was available. Among SAD patients, the prevalence of aPL differs significantly between two groups: SLE (57.6%) and non-SLE SADs (13.7%, p < 10-4). Next, association between aPL plus thrombosis and miscarriage were observed in both SLE and non-SLE patients. Thrombosis was best predicted in SLE patients by dRVVT (OR = 6.1; IC95:3.5-10.3) and miscarriage by aCL±β2GPI IgG (OR = 2.5; IC95:1.2-5.2); while in non-SLE SADs the best predictors were aCL±β2GPI IgG for thrombosis (OR = 6.6; IC95:2.4-18.4) and aCL±β2GPI IgM for miscarriage (OR = 2.9; IC95:1.2-6.8). In the case of multiple positivity of aPL, the risk for thrombosis and miscarriage was increased. Central nervous system involvement characterized the SLE patients, in contrast to pulmonary and skin fibrosis, valve lesions, hypertension, elevated creatinemia, C4 fraction reduction, platelet reduction and inflammation that characterized the non-SLE SAD patients. Anti-PL determination remains important in SADs patients and should not be restricted to only SLE patients

Analytical performance of the chemiluminescent analyzer IDS-Isys for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I

International audienc

Analytical performance of the chemiluminescent analyzer IDS-Isys for the detection of anti-cardiolipin and anti-beta 2 glycoproteine I autoantibodies.

International audienc

Analytical performance of the chemiluminescent analyzer IDS-Isys for the detection of anti-cardiolipin and anti-beta 2 glycoproteine I autoantibodies.

International audienc

Analytical performance of the chemiluminescent analyzer IDS-Isys for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I

International audienc